Published in Clin Pharmacol Ther on July 01, 2003
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension (2011) 1.60
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol Dial Transplant (2009) 1.49
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther (2008) 1.37
Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension. J Postgrad Med (2014) 1.25
Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets. Biochim Biophys Acta (2006) 1.15
Pharmacogenetics of beta-blockers. Pharmacotherapy (2007) 1.13
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther (2011) 1.11
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.09
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics (2008) 1.04
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.01
Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.97
Chapter 7: Pharmacogenomics. PLoS Comput Biol (2012) 0.96
Dissecting complex traits: recent advances in hypertension genomics. Genome Med (2009) 0.93
The functional significance of genetic variation within the beta-adrenoceptor. Br J Clin Pharmacol (2005) 0.93
Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics (2009) 0.90
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics (2009) 0.87
Genetic variation, β-blockers, and perioperative myocardial infarction. Anesthesiology (2011) 0.87
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. Pharmacol Rev (2016) 0.87
PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme. Pharmacogenet Genomics (2010) 0.86
Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol (2015) 0.85
An update on the pharmacogenetics of treating hypertension. J Hum Hypertens (2014) 0.84
Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol Genomics (2008) 0.84
Advancing management of hypertension through pharmacogenomics. Ann Med (2012) 0.84
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival. BMC Med Genet (2008) 0.84
G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. Circ Cardiovasc Genet (2014) 0.84
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr Opin Cardiol (2009) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
β2 adrenergic receptor polymorphisms and nocturnal blood pressure dipping status in the Wisconsin Sleep Cohort Study. J Am Soc Hypertens (2011) 0.83
Progress and future aspects in genetics of human hypertension. Curr Hypertens Rep (2013) 0.82
Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev (2008) 0.81
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur J Clin Pharmacol (2005) 0.81
Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med (2013) 0.81
Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance. Int Arch Occup Environ Health (2005) 0.80
Polymorphisms in α- and β-Adrenergic Receptor Genes, Hypertension, and Obstructive Sleep Apnea: The Skaraborg Sleep Study. Int J Hypertens (2010) 0.80
Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob Cardiol Sci Pract (2014) 0.80
The Gly389Arg beta1-adrenergic receptor polymorphism: a predictor of response to beta-blocker treatment? Clin Pharmacol Ther (2003) 0.80
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PLoS One (2013) 0.78
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach. Psychopharmacol Bull (2010) 0.77
Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res (2016) 0.77
Genome-wide approach to identify novel candidate genes for beta blocker response in heart failure using an experimental model. Discov Med (2011) 0.77
Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker? J Geriatr Cardiol (2011) 0.77
Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress echocardiography. Eur J Clin Pharmacol (2011) 0.77
Pharmacogenomics and migraine: possible implications. J Headache Pain (2008) 0.76
Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method. Hum Genomics (2016) 0.76
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
Cardiovascular drugs and the genetic response. Methodist Debakey Cardiovasc J (2014) 0.75
Pharmacogenetics of cardiovascular drug therapy. Clin Cases Miner Bone Metab (2009) 0.75
Emerging strategies and applications of pharmacogenomics. Hum Genomics (2004) 0.75
Personalized medicine and treatment approaches in hypertension: current perspectives. Integr Blood Press Control (2016) 0.75
The Pharmacogenomics of Anti-Hypertensive Therapy. Pharmaceuticals (Basel) (2010) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
A case for pharmacogenomics in management of cardiac arrhythmias. Indian Pacing Electrophysiol J (2012) 0.75
ADRB1 variants in atrial fibrillation: small steps and giant leaps toward personalized therapy in cardiovascular disease. J Am Coll Cardiol (2012) 0.75
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail (2009) 2.89
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Centrographic analysis of 1-phase versus 2-phase treatment for Class II malocclusion. Am J Orthod Dentofacial Orthop (2005) 2.35
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.30
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 2.20
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail (2008) 2.09
Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med (2005) 2.08
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov (2013) 1.78
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Effectiveness of early treatment of Class II malocclusion. Am J Orthod Dentofacial Orthop (2002) 1.48
Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta (2006) 1.46
Quality of life and economic burdens of malocclusion in U.S. patients enrolled in Medicaid. J Am Dent Assoc (2010) 1.46
Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J (2003) 1.45
Continuing to strengthen FDA's science approach to emerging technologies. Nanomedicine (2013) 1.43
The slow cardiac myosin regulatory light chain in heart failure. Clin Cardiol (2011) 1.43
CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. J Clin Psychiatry (2012) 1.42
QRS duration variability in patients with heart failure. Am J Cardiol (2002) 1.42
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail (2006) 1.41
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens (2009) 1.40
The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci (2013) 1.38
The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J (2009) 1.36
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
The Digital Divide and urban older adults. Comput Inform Nurs (2010) 1.22
The effect of dyadic intervention on self-efficacy, social support, and depression for men with prostate cancer. Psychooncology (2004) 1.22
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics (2010) 1.17
Early outcomes of a care coordination-enhanced telehome care program for elderly veterans with chronic heart failure. Telemed J E Health (2005) 1.16
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics (2007) 1.15
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension (2009) 1.15
An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Interv Cardiol (2010) 1.14
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Mental stress provokes ischemia in coronary artery disease subjects without exercise- or adenosine-induced ischemia. J Am Coll Cardiol (2006) 1.12
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther (2002) 1.11
The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol (2007) 1.10
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation (2003) 1.07
Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J (2002) 1.06
Assessment of glycated hemoglobin using A1CNow+ point-of-care device as compared to central laboratory testing. J Diabetes Sci Technol (2008) 1.05
Depression among southern rural African American women: a factor analysis of the Beck Depression Inventory-II. Nurs Res (2004) 1.04
Implication of the melanocortin-3 receptor in the regulation of food intake. Eur J Pharmacol (2011) 1.02
Racial disparity in oral and pharyngeal cancer in Florida in 1991-2008: mixed trends in stage of diagnosis. Community Dent Oral Epidemiol (2012) 0.99
Management of heart failure after cardiac resynchronization therapy: integrating advanced heart failure treatment with optimal device function. J Am Coll Cardiol (2005) 0.98
A comparison of treatment impacts between Invisalign aligner and fixed appliance therapy during the first week of treatment. Am J Orthod Dentofacial Orthop (2007) 0.97
Tricuspid annular motion as a predictor of severe right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant (2008) 0.95
Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism (2008) 0.94
Estrogen and different aspects of vascular disease in women and men. Circ Res (2006) 0.94
Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry (2011) 0.94
Comparison of peer assessment ratings (PAR) from 1-phase and 2-phase treatment protocols for Class II malocclusions. Am J Orthod Dentofacial Orthop (2003) 0.94
Changes in circulating satiety hormones in obese children: a randomized controlled physical activity-based intervention study. Obesity (Silver Spring) (2010) 0.93
Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail (2011) 0.92
CNS inflammation and bone marrow neuropathy in type 1 diabetes. Am J Pathol (2013) 0.92
Timing of Class II treatment: skeletal changes comparing 1-phase and 2-phase treatment. Am J Orthod Dentofacial Orthop (2007) 0.92
Preparation and anesthetic properties of propofol microemulsions in rats. Anesthesiology (2006) 0.91
Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy (2006) 0.91
Lipid-lowering medication use and aggression scores in women: a report from the NHLBI-sponsored WISE study. J Womens Health (Larchmt) (2008) 0.90
Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.90
Symptoms, myocardial ischaemia and quality of life in women: results from the NHLBI-sponsored WISE Study. Eur Heart J (2003) 0.90
Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation (2002) 0.89
Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant (2008) 0.89
Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology (2005) 0.89
Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts. J Heart Lung Transplant (2007) 0.89
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy (2011) 0.88
Monitoring uterine activity during labor: a comparison of 3 methods. Am J Obstet Gynecol (2012) 0.88
Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials. Circ Heart Fail (2013) 0.87
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med (2012) 0.87
Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. Pharmacogenomics (2013) 0.87
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. J Transl Med (2008) 0.86
Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. Pharmacotherapy (2006) 0.85
HIV and older adults: clinical outcomes in the era of HAART. J Gerontol Nurs (2004) 0.85
Retracted Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding. Hum Reprod (2006) 0.85
APOE polymorphism and angiographic coronary artery disease severity in the Women's Ischemia Syndrome Evaluation (WISE) study. Atherosclerosis (2003) 0.85
Orthodontic tooth movement with clear aligners. ISRN Dent (2012) 0.85
Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Clin Cardiol (2009) 0.84
An examination of eating behaviors, physical activity, and obesity in african american adolescents: gender, socioeconomic status, and residential status differences. J Pediatr Health Care (2015) 0.82
Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization. J Clin Pharmacol (2015) 0.82
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics (2011) 0.82
Death rattle is not associated with patient respiratory distress: is pharmacologic treatment indicated? J Palliat Med (2013) 0.82
Survivorship after prostate cancer treatment: spouses' quality of life at 36 months. Oncol Nurs Forum (2013) 0.82
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs. Pharmacogenomics (2010) 0.82
Complementary and alternative medicine use among individuals participating in research: implications for research and practice. Pharmacotherapy (2006) 0.81
Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens (2003) 0.81
Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study. J Lipid Res (2011) 0.81